Novartis Launches C. perfringens Swine Vaccine

August 16, 2006 — 
  [ES]

Novartis Animal Health US, Inc. has been granted a conditional license to market a Clostridium perfringens Type A Toxoid for use in swine.

According to Duncan Rowe, director of the Novartis swine business unit, "Novartis scientists have developed a way to produce and inactivate sufficient quantities of the alpha toxin to satisfy USDA conditional license efficacy requirements." A Novartis press release indicates that the toxoid "includes a proprietary dual-component adjuvant formulation that plays an important role in the effectiveness of this vaccine. It is safe for use in healthy swine, including bred gilts or sows and feeder pigs."

The vaccine is labeled for the control of diarrhea associated with C. perfringens infections. The clinical signs are often observed in pigs within the first week of life.

Additional information is available on the Novartis website http://www.livestock.novartis.com or by calling 800-843-3386.